Genmab — November 2017
-
Du har da ret, men jeg er alligevel meget spændt på om der kommer et abs på Alcyone på tirsdag og om data er gode. Ikke så meget fordi Alcyone i sig selv er så pokkers vigtig, men det vil pege frem mod endnu bedre data i Maia - og det er vigtigt pga det amerikanske marked.
-
Flash Nordea "At the SITC conference last week (8-12 November) in National Harbor, Maryland, JnJ showcased its own CD38 preclinical data in lung cancer (NSCLC) as well as early data for its in-house developed anti-PD-1 antibody JNJ-283. We find the data and presentations highly interesting in a Genmab context. First of all, with regards to the CD38 preclinical data in NSCLC, it is, to our knowledge, the first time we see JnJ’s in-house early data for CD38 in solid cancers.
-
We have previously seen data from JnJ explaining the potential effect of Daratumumab (Darzalex – CD38) on the tumour micro-environment, but that has been from trials in multiple myeloma (depletion of T-regulatory and B-regulatory cells). We have also seen data from Chen et al from MD Anderson Cancer Centre at ASCO-SITC back in February 2017 highlighting very intriguing preclinical results in lung cancer tumours when CD38 was combined with PD-L1.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind